T2D, Obesity and Heart Failure: Breaking the Pathophysiologic Triangle Dr. Kamal Kant Kohli19 March 2026 10:15 AM ISTIndia's diabetes burden has risen markedly, with 101 million individuals living with diabetes. The clinical burden is compounded by heart failure...
T2D and CKD Risk: Can Weight Loss Alter Kidney Outcomes? Dr. Kamal Kant Kohli16 March 2026 11:03 AM ISTType 2 diabetes mellitus (T2DM) represents a mounting global health crisis. India, home to 17.78% of the world's population, ranks second globally...
The Adiposity-Inflammation Axis in T2D: Implications for Heart and Kidney Dr. Kamal Kant Kohli13 March 2026 10:57 AM ISTIndia is home to nearly 90 million people with T2DM , with an estimated 39.4 million remaining undiagnosed. Recent estimates from India indicate...
MASLD in T2D: Why Weight Loss Is More Than Cosmetic? Dr. Kamal Kant Kohli10 March 2026 10:26 AM ISTIndia's diabetes burden is escalating rapidly, with 101 million adults currently living with T2DM (ICMR-INDIAB Study)1. Compounding this crisis,...
Beyond Glycaemia- Weight Reduction Is the New Additional Therapeutic Endpoint in T2D Dr. Kamal Kant Kohli7 March 2026 10:59 AM ISTIndia bears a disproportionate share of the global diabetes burden, with 89.8 million adults living with T2DM against a worldwide estimate of 589...
Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025 Dr. Manoj Chadha19 Feb 2026 10:35 AM ISTHyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating...
Redefining Diabetes Management With Dapagliflozin and Sitagliptin FDC: An Early, Effective and Sustainable Option For T2D Management With Risk Factors Dr. Vaishali Deskhmukh12 Feb 2026 12:40 PM ISTType 2 diabetes in Indians follows a distinct and more aggressive trajectory, marked by higher insulin resistance, early Beta-cell dysfunction, lower...
Obesity-Prediabetes Duo: Why Clinicians Must Intervene Early? Dr. Siddhant Milind Dahale4 Feb 2026 12:30 PM ISTPrediabetes is alarmingly common, with the IDF 2025 Atlas estimating nearly 90 million Indians are affected. [1] Escalating obesity,...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Dapagliflozin and Sitagliptin FDC in T2D with Heart Failure: 2025 Indian Practice Review Dr. Santosh H.S.17 Jan 2026 11:39 AM ISTAmong India's 89.8 million people with T2D [1], heart failure incidence reaches approximately 50%, with 33% higher hospitalization risk versus...
Latest Triple Combination of Empagliflozin, Sitagliptin, and Metformin for Advanced Care in Indian T2DM Patients- When to Consider? Dr. (Col) Sudhir Tripathi9 Jan 2026 11:37 AM ISTDiabetes mellitus affects nearly 90 million Indians (IDF 2025) [1], with the Indian phenotype conferring disproportionately higher cardiorenal risk...
Uncontrolled T2DM in India and Application of Trusted Molecules Empagliflozin, Sitagliptin, and Metformin Coming Together Dr. Sunil M Jain10 Dec 2025 11:13 AM ISTThe Growing Burden of Uncontrolled T2DM in India: The burden of diabetes in India has risen markedly, yet only around 7% of individuals with diagnosed...
